Evidence map›Paper›PMID 42732034›Full record

ArticleMolecular diversity2026

HD-SKRG: a hierarchical dual-view and structure-knowledge relation graph enhancement network for few-shot molecular property prediction.

Luyi Jia, Mingyang Wang, Zeming Wang, Xianjie Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Luyi JiaNortheast Forestry University, Harbin, 150040, China.
Mingyang WangNortheast Forestry University, Harbin, 150040, China. wangmingyang@nefu.edu.cn.
Zeming WangNortheast Forestry University, Harbin, 150040, China.
Xianjie WangHarbin Institute of Technology, Harbin, 150001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Few-shot molecular property prediction aims to adapt to new property tasks using only a few labeled molecules. However, existing methods are still limited by insufficient molecular representations and biased intra-task relation construction under scarce supervision. To address these limitations, this paper proposes HD-SKRG, a hierarchical dual-view and structure-knowledge relation graph enhancement network. HD-SKRG improves few-shot prediction from two complementary aspects: molecular representation learning and intra-task relation propagation. For molecular representation, HD-SKRG builds atom-level and functional-group-level graphs, injects elemental knowledge into atom representations, and transfers local atomic information to functional-group representations. A frequency-aware aggregation module further produces molecular-level knowledge representations. For intra-task relation propagation, the structure relation graph provides the main feature-propagation pathway, whereas the knowledge relation graph supplies semantically related neighbors and refines relation weights. This design reduces graph-construction bias caused by relying on structural similarity alone. The dual-view encoders are pretrained by cross-view contrastive learning, and the full model is meta-trained under the MAML framework. Experiments on Tox21, SIDER, MUV, and ToxCast under 1-shot and 10-shot settings show that, HD-SKRG achieves the best results in five of eight settings and the second-best results in the remaining three. Ablation studies further confirm the contribution of each module.

Indexed as

Few-shot molecular property predictionHierarchical molecular representationMeta-learningRelation graph learning

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.